RxDoctor Payments Data

Jada Rausch, NP

Family · Pierre, SDNPI 1578028981

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 223 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,357in general payments, 2019–2025

Across 223 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$635
  • Amgen$481
  • Pfizer$438
  • E.r. Squibb & Sons, L.L.C.$414
  • Novo Nordisk$287
  • Astellas Pharma US Inc$254
  • plus $847 from 16 others

What the payments were for

  • Food & beverage$3,357100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,357 in reported general payments places this provider in the 90th percentile of 588 family providers in South Dakota.

See all family providers in South Dakota

Medicare billing

Part B allowed, 2024
$25,713
Medicare patients
131
Services billed
326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$25,444
EliquisApixaban31$24,134
JardianceEmpagliflozin25$22,198
MounjaroTirzepatide12$14,906
TrulicityDulaglutide15$14,142
DuleraMometasone/Formoterol11$3,912
Potassium Chloride54$1,608
Gabapentin46$1,243
Diltiazem 24hr Er (Cd)Diltiazem Hcl16$1,225
Atomoxetine Hcl12$1,225
Metoprolol Succinate60$1,169
Atorvastatin Calcium99$898
Albuterol Sulfate HfaAlbuterol Sulfate29$857
SynthroidLevothyroxine Sodium14$818
Pantoprazole Sodium42$799

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$635$29,04827 claims
Novo NordiskOzempic$287$25,44429 claims
PfizerEliquis$438$24,13431 claims
Boehringer IngelheimJardiance$114$22,19825 claims
MerckDulera$15$3,91211 claims
AbbVieSynthroid$66$81814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 588 family providers in South Dakota.

Other family in Pierre

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →